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Objective: Ovarian senescence affects many tissues and produces a variety of symptoms and signs. We
hypothesized that estrogens may also inﬂuence circulating redox balance by regulating activity of the
cellular antioxidative enzyme system. We aimed to explore the impact of surgical estrogen deprivation
and replacement (ERT) on the glutathione balance and antioxidant enzymes expression in fertile women.
Study design: Nineteen healthy premenopausal womenwho underwent total hysterectomy with bilateral
salpingo-oophorectomy were evaluated at baseline, 30 days after surgery without ERT and 30 days after
ERT. Redox balance was determined by measuring blood reduced (GSH) and oxidized (GSSG) glutathione,
as well as the GSSG/GSH ratio. Antioxidant status was evaluated by measuring serum estrogen (E2) levels
and mRNA expression of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px)
and glutathione S-transferase (GST) in peripheral blood mononuclear cells.
Results: Serum E2 signiﬁcantly lowered after surgery, and increased in 12 out of 19 patients after 30 days
of ERT (Responders). In such patients, an increase in oxidative stress was observed after surgery that
resolved after ERT. Oxidative stress was sustained by reduction in the mRNA expression of both SOD and
GSH-Px, that recovered after 30 days of therapy in responders. CAT and GST mRNA expression were not
modiﬁed by surgery and replacement therapy.
Conclusions: Menopause is associated with signiﬁcant change in antioxidant gene expression that in turn
affects circulating redox state. Estrogens replacement therapy is able to prevent and counteract such
modiﬁcations by acting as regulators of key antioxidant gene expression. These ﬁndings suggest that
antioxidant genes are, almost in part, under the control of sex hormones, and that pathophysiology of the
difference in gender disease may depend on the redox biology.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY-NC-ND license.Introduction
Ovarian senescence occurs gradually during the fourth and ﬁfth
decades of life, leading to menopause. This process is associated
with a progressive decline in estrogen level, which affects many
tissues of the body and produces a variety of signs and symptoms
[1]. In contrast, surgical removal of the ovaries interrupts abruptly
and completely estrogen production, leading to more severe
symptoms than those generated by natural menopause [2,3].
Bilateral oophorectomy at the time of hysterectomy for benignr B.V.
@gmail.com (G. Serviddio).
this work.
Open access under CC BY-NC-NDdisease is commonly practiced in order to prevent the subsequent
development of ovarian cancer [4]. However, premenopausal
oophorectomy causes a rapid decline in circulating ovarian estro-
gens and androgens, since postmenopausal ovaries continue to
produce signiﬁcant amounts of testosterone and androstenedione
which are converted to estrogen peripherally [5,6]. Estrogen
depletion caused by oophorectomy is associated with coronary
heart disease and hip fractures, as well as higher risk of cognitive
impairment, depression and anxiety [7–9]. Symptoms and patho-
logical manifestations associated with menopause may be, in part,
related to oxidative stress [10]. Oxidative stress is deﬁned as an
imbalance between oxidants (superoxide anion radical, hydrogen
peroxide, hydroxyl radical, peroxynitrite) and antioxidants (enzy-
matic and non enzymatic) in favor of the former [11].
Oxidative stress is higher in postmenopausal women, suggest-
ing that antioxidant status may be related to estrogen deﬁcit
[12,13]. Surgical menopause is also associated with elevated
production of oxidants, but estrogen counteracts oxidative stress, license.
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antioxidant effect; in fact, estrogen level positively correlates with
plasma antioxidant capacity and antioxidant enzymes expression
throughout the menstrual cycle [15–17], and negatively with lipid
peroxides, the product of oxidative damage [18]. Very interest-
ingly, estrogen replacement therapy (ERT) restores total plasma
antioxidant capacity and decreases lipid peroxides [18,19].
The antioxidant effect of estrogen may be related to a direct
free radical scavenging activity [20]. However, the circulating level
and the administered doses of estrogen are much lower than the
necessary concentration of classical chemical antioxidants, indi-
cating that its antioxidant effects is likely related to the upregula-
tion of antioxidant enzymes [21]. Such hypothesis has been
veriﬁed by in vitro and ex vivo animal studies [22,23]; never-
theless, the relationship between estrogen and the antioxidant
enzymes system has been so far not addressed in humans. Thus,
we aimed to investigate the impact of estrogen level change
(depletion and replacement) and antioxidant gene expression
and circulating redox balance in premenopausal women under-
going bilateral oophorectomy.Materials and methods
Study design
Nineteen consecutive premenopausal women, referred the
Department of Obstetrics and Gynecology of the University of Foggia
for benign gynecological disease, who did not respond to standard
medical treatments and with no indication for endometrial ablation,
underwent hysterectomy and bilateral oophorectomy.
Exclusion criteria were Body Mass Index (BMI) ≥30 kg/m2, a
previous hospital admission related to cardiovascular disease, and
a previous diagnosis of angina, hypercholesterolemia, diabetes,
alcoholism, thyroid or any other endocrine disease. In addition,
none of them had smoking habits or had taken medications, as
well as contraceptive drugs, vitamin supplements and soy deriva-
tives in the 6 months before the study. The subjects were asked to
record any consumption of drugs not included in the experimental
design. Study participants were assigned to a 60-day experimental
period: 30 days after oophorectomy, they received 50 micrograms/
day of continuous trans dermal in the form of patches (Dermestril,
Rottapham S.p.A., Milan, Italy). The study protocol was approved
by the institutional review board and the local Ethics Committee,
and all patients gave written informed consent. Evaluation of
treatment compliance was ascertained by weekly interview.
Blood sampling and analysis
Blood samples were collected the day before the surgical
oophorectomy (Baseline time), 30 days after oophorectomy and
before starting estrogen replacement therapy (Menopause time)
and 30 days after starting therapy (ERT time) from an antecubital
vein between 8:00 and 9:00 AM, with subjects in the supine
position after an overnight fast. Blood samples for estradiol
measurement were collected in 8 mL-Vacutainer tubes containing
Z Serum Sep Clot Activator (Greiner Bio-one Gmbh, Frickenhausen,
Germany) and centrifuged for 10 min at 1600 g at room tem-
perature to isolate serum. Blood samples for RNA isolation were
collected into tubes containing K-ethylenediaminetetraacetic acid
(EDTA) and processed within 30 min.
Oxidized (GSH) and reduced (GSSG) glutathione were deter-
mined in whole blood as previously described [25]. Brieﬂy, blood
samples were treated with an equal volume of 6% (v/v) perchloric
acid containing 1 mM EDTA to determine GSH or with 6%
perchloric acid containing 50 mM N-ethylmaleimide and 1 mMEDTA to determine GSSG by high-performance liquid chromato-
graphy (HPLC). Afterwards, samples were centrifuged for 10 min at
1500 g and the acidic supernatants were neutralized and used
for determination of metabolites.
Serum concentration of estrogen (E2), progesterone, follicle
stimulating hormone (FSH) and luteinizing hormone (LH) were
measured using commercial chemiluminescence immunoassays
(Vitros Estradiol, Johnson & Johnson Medical S.p.A., Milan, Italy).
RNA isolation and quantitative real-time reverse-transcription
polymerase chain reaction (qRT-PCR)
Total cellular RNA was isolated from peripheral blood mono-
nuclear cell (PBMC) samples using the RNAeasy Kit (Qiagen,
Hilden, Germany) according to the manufacturer instructions.
To ensure minimum in vitro impact on the activation status of
the cells, we employed a modiﬁed gradient separation. PBMC were
immediately isolated by a rapid Ficoll–Hystopaque centrifugation
for 30 min at 900 g. Total cellular RNA was extracted with
RNeasy kit and immediately stored at −80 1C. Samples were
quantiﬁed by absorption spectrophotometry, and RNA integrity
was conﬁrmed using nondenaturing agarose gel electrophoresis.
cDNA was obtained using a random hexamer primer and a Super-
Script III Reverse Transcriptase kit as described by the manu-
facturer (Invitrogen, Frederick, MD, USA). A PCR master mix
containing the speciﬁc primers (superoxide dismutase 1 (SOD1):
forward, TGT GGG GAA GCA TTA AAG G; reverse, CCG TGT TTT CTG
GAT AGA GG; catalase (CAT): forward, GCC ATT GCC ACA GGA AAG
TA; reverse, CCA ACT GGG ATG AGA GGG TA; glutathione perox-
idase (GSH-Px): forward, GGA GAC CTC ACC CTG TAC C; reverse,
GTC ATT CAC CAT GTC CAC C; glutathione S-transferase (GST):
forward, ACC TCC ACC GTA TAT TTG AG; reverse, TTG CCC CAG ACA
GCC ATC TT; glyceraldehyde-3-phosphate dehydrogenase
(GAPDH): forward, CAA GGC TGA GAA CGG GAA; reverse: 59-
GCA TCG CCC CAC TTG ATT TT-39) was added, along with
AmpliTaq Gold DNA polymerase (Applied Biosystems, Foster City,
CA, USA). Real-time quantiﬁcation of mRNA was performed with a
SYBR Green I assay, and evaluated using an iCycler detection
system (Bio-Rad Laboratories). The threshold cycle (CT) was
determined, and the relative genes expression was subsequently
calculated as follows: fold change¼2−Δ(ΔCT), where ΔCT¼CTtar-
get−CThousekeeping and Δ(ΔCT)¼ΔCTtreated−ΔCTcontrol.
Statistical analysis
Data were expressed as mean7standard deviation of the mean
(SDM). For biochemical and real-time RT-PCR data, the one way
analysis of variance (ANOVA) for repeated measures was per-
formed to compare results obtained before vs. after oophorectomy
and ERT. Bonferroni's multiple comparison test was performed as
post-hoc test. The student's t-test was used for paired data.
A linear regression model was used to analyze the association
between serum E2 levels and SOD, CAT, GSTP, GSTM levels, as well
as GSH, GSSG and GSSG/GSH ratio, at all the times studied. A value
of po0.05 was considered statistically signiﬁcant. The Statistical
Package for Social Sciences (SPSS v. 15) was used to perform all the
statistical analysis.Results
Baseline patients characteristics
Baseline characteristics of patients are shown in Table 1. Nine
patients (47%) were overweight (BMI425 kg/m2), four patients
(21%) presented history of arterial hypertension (systolic blood
Table 1
Clinical and biochemical features of patients
enrolled in the study at the baseline time point.
(n¼19)
Age
Mean7SD 4873.9
Weight
Mean7SD 6577.5
Range 50–79
Body mass index (kg/m2)
Mean7SD 26.072.9
Range 19.8–29.8
Plasma hemoglobin (g/dL)
Mean7SD 12.571.5
Range 10.8–13.9
Serum estradiol (pg/mL)
Mean7SD 156.6794.8
Range 50–350
Serum progesterone (ng/mL)
Mean7SD 3.674.8
Range 0.2–11.9
Serum FSH (U/L)
Mean7SD 8.575.2
Range 1.8–17.5
Serum LH (nmol/L)
Mean7SD 10.978.7
Range 2.8–33.1
FSH, follicle stimulating hormone; LH, luteinizing
hormone.
Table 2
Blood level of GSSG/GSH ratio, reduced (GSH) and oxidized (GSSG) glutathione,
mRNA expression of superoxide dismutase (SOD), catalase (CAT), glutathione
peroxidase (GSH-Px) and glutathione-S-transferase (GST) in peripheral blood
mononuclear cells from 19 women at baseline and 30 days after surgical
menopause (Menopause). Statistical differences were assessed using Student's t-
test for repeated measures.
Baseline
(mean7SD)
Menopause
(mean7SD)
Blood GSSG/GSH ratio (%) 9.4672.15 14.2875.64nn
Blood GSH (nmol/L) 54.69712.28 39.28710.42n
Blood GSSG (nmol/L) 4.9871.32 7.4072.63n
SOD mRNA expression (%) 100724.48 64.20729.56nn
CAT mRNA expression (%) 100736.72 89.31731.55
GSH-Px mRNA expression
(%)
100731.94 42.66725.88nn
GST mRNA expression (%) 100729.33 88.43721.28
n po0.05 vs. T0.
nn po0.01 vs. T0.
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Six patients (31%) had a plasma hemoglobin value o12 g/dL at
baseline; these patients reported to have irregular menstrual cycle
with metrorrhagia. Of note, no association was found between BMI
and serum estrogen level in all the subjects studied. The com-
pliance of women to ERT was complete.
Effect of surgery on circulating redox balance and antioxidant
enzymes expression
Table 2 shows the change of glutathione status 30 days after
oophorectomy as compared to the baseline. We observed both a
decrease in GSH and an increase in GSSG blood level, and
consequently an increase in GSSG/GSH ratio, consistent with an
impaired redox balance. Moreover, surgical menopause was asso-
ciated with a reduction in SOD and GSH-Px mRNA gene expres-
sion, while no modiﬁcations were observed in the expression of
CAT and GST (Table 2).
ERT restored redox balance by inducing antioxidant genes expression
Administration of estrogen for 30 days in surgical post-
menopausal women induced a signiﬁcant increase in the circulat-
ing E2 level as reported in Fig. 1. The mean level of E2 was
157.63789.97 pg/mL before the surgery and 13.0179.40 pg/ml
after ovariectomy. After ERT, patients with E2 levels of at least
50 pg/mL were considered responders. The analysis of the cases
evidenced that the level of E2 reached 50 pg/mL in 12 out 19
patients (63%) after 30 days replacement treatment; the remaining
seven patients (37%) were considered non-responders (Fig. 1). The
analysis of circulating redox balance revealed a signiﬁcant con-
sumption of reduced glutathione and a production of oxidized
glutathione suggesting that oophorectomy induced oxidative
stress that was counteracted by ERT (Fig. 1B and D). To better
analyze the impact of estrogen deprivation on the circulatingredox balance the responders and non responders women were
compared in terms of redox state. In womenwho responded to the
ERT the level of reduced glutathione resulted higher and the GSSG
lower as compared to non responders; as a consequence, the blood
GSSG/GSH ratio decreased 30 days after ERT (Fig. 2).
Taken together our data suggest that estrogen depletion decreases
the antioxidant capacity of the woman that may be counteracted by
estrogen replacement. To verify the mechanism accountable for such
effect, the analysis of the mRNA expression of genes encoding
for several antioxidant enzymes (SOD, CAT, GSH-Px and GST) was
performed by real time RT-PCR in the responder group. As reported
in Fig. 3, the expression of the SOD and GSH-Px genes was completely
recovered after treatment. In contrast, GST expression seemed to be
not modulated by estrogen; however, CAT seemed to be tightly
regulated by circulating estrogen change (Fig. 3).Relationship between serum E2 levels and blood glutathione balance,
as well as antioxidant gene expression
To assess the relationship between E2 changes and redox
balance, a linear regression model was designed to correlate the
variation of serum E2 level (independent variable) and the varia-
tion of GSH, GSSG and GSSG/GSH ratio, as well as antioxidant gene
expression in the responders patients as dependent variables, and
the results are reported in Fig. 4. A signiﬁcant positive relationship
was observed between the E2 (ΔE2) and GSH, SOD and GSH-Px;
in contrast, change in E2 negatively correlated to GSSG and GSSG/
GSH ratio. The change in E2 level, was, however, not able to predict
modiﬁcation of CAT and GST gene expression (Fig. 4).Discussion
The present study shows that in women there is a linear
relationship between the level of circulating estrogen and the
antioxidant status; in addition, we report that surgical menopause
induced an imbalance in the redox status that can be prevented by
estrogen replacement therapy.
Very interestingly, here we report that estrogen acts as a
positive signal in gene control of antioxidant mRNA expression
which in turn modulates redox balance.
Bilateral oophorectomy-induced menopause has been asso-
ciated with increasing plasma malondialdehyde [16]. Supplemen-
tation of E2 after menopause decreases serum lipid peroxides and
restores total plasma antioxidant capacity [18,24]. Several studies
Fig. 1. (A) Serum level of estrogen (E2) in 19 women that underwent hysterectomy and bilateral oophorectomy at baseline (B), after surgical menopause (SM) and after 30
days of estrogen replacement therapy (ERT). (B–D) Blood level of reduced (GSH) and oxidized (GSSG) glutathione, and GSSG/GSH ratio in 12 women that underwent
hysterectomy and bilateral oophorectomy and responded to estrogen replacement therapy (ERT) at baseline (B), 30 days after surgical menopause (SM) and 30 days after
ERT. Statistical differences were assessed using one-way ANOVA for repeated measures with Bonferroni's multiple comparison test as post-hoc test.
Fig. 2. Blood level of reduced (GSH) and oxidized (GSSG) glutathione, and GSSG/GSH ratio in responder (n¼12) and non responder (n¼7) women in surgical menopause to
30 days of estrogen replacement therapy. Data are expressed as mean7standard deviation of the mean. Statistical differences were assessed using Student's t-test for
unpaired measures.
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both in vitro and in vivo, suggesting that E2 could exert a role
in the control of the antioxidant signaling pathways [26,27].
The novelty of the present study was in the model applied where
the analysis of the change of circulating redox activity and
gene expression was performed in the same patients beforesurgical oophorectomy, during estrogen deprivation after surgical
procedure, and after restoring normal E2 level. Our data show,
for the ﬁrst time, that circulating redox state is closely modu-
lated by E2 level and that estrogen depletion exposes the patient
to the risk of oxidative stress. The intracellular antioxidant
system is based on the glutathione, which plays a key role in cellular
Fig. 3. mRNA expression of superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px) and glutathione-S-transferase (GST) in peripheral blood
mononuclear cell of 12 women that underwent hysterectomy and bilateral oophorectomy and responded to estrogen replacement therapy (ERT) at baseline (B), 30 days after
surgical menopause (SM) and 30 days after ERT. Data are expressed as mean7standard deviation of the mean. Statistical differences were assessed using one-way ANOVA
for repeated measures with Bonferroni's multiple comparison test as post-hoc test.
Fig. 4. Linear regression analysis between the variations of serum E2 level (ΔE2) and superoxide dismutase (ΔSOD), glutathione peroxidase (ΔGSH-Px) mRNA expression, as
well as reduced (ΔGSH) and oxidized (ΔGSSG) glutathione, and GSSG/GSH ratio (ΔGSSG/GSH), expressed as the difference between 30 days after estrogen replacement
therapy (ERT) and 30 days after surgical menopause, in 12 women that underwent hysterectomy and bilateral oophorectomy and responded to ERT.
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status [28]. This tripeptide can exist intracellularly in either an
oxidized (GSSG) or reduced (GSH) state. Maintaining optimal GSSG/
GSH ratio in the cell is critical to survival, hence, the antioxidant
equilibrium is tightly regulated [29]. A recent report showed a higher
GSSG/GSH ratio in oophorectomized aged rats [30], and Bednarek-
Tupikowska et al. reported a linear relationship between estrogen
and GSH-Px in erythrocytes of postmenopausal women [16].
In addition to glutathione, several antioxidant enzymatic
systems, including superoxide dismutase (SOD), catalase (CAT),
glutathione peroxidase (GSH-Px) and glutathione S-transferase
(GST) transform reactive free radicals into less reactive, or inactive
species. There are contrasting evidences about the effects of
menopause and hormone replacement therapy on the activities
of these enzymes [12,31,32]. Studies performed in liver homo-
genates or femurs of oophorectomized rats evidenced reduced
activities of SOD, CAT, GSH-Px and GST [33,34]. A recent study
reported the effect of E2 supplementation on lipid oxidation and
catalase activity [24]; however, no data concerning the effect of E2
deprivation on the entire antioxidant enzyme system are available
in humans.
The regulatory effects of estrogen are mediated by tran-
scriptional activation of estrogen-responsive genes, involving
intracellular estrogen receptors [35,36]. As ligand-dependent tran-
scriptional factors, the hormone-bound estrogen receptors interact
with estrogen response elements to stimulate several genes in
estrogen-responsive tissues and to regulate gene trans-activation
[37]. Estrogen in vitro activate MAPK and NFκB, driving the
expression of the antioxidant enzymes SOD and GSH-Px [21].
Another evidence provided on skeletal muscle of oophorecto-
mized mice reported that estrogen replacement increased anti-
oxidant gene expression via Estrogen Receptor α [23]. Our data
deﬁnitively support such observation.
Very interestingly, we did not observe any variation in the
expression of GST, which is considered a phase II enzyme,
catalyzing conjugation reactions that convert the highly reactive
species produced during phase I metabolism to less reactive
products. It has been demonstrated that E2 may inhibit phase II
enzymes expression via a pathway involving NRF2 and the
antioxidant response element [38,39]. Even though a repression
of GST has not been reported in the current study, we could
speculate that variations in the E2 level did not signiﬁcantly
inﬂuence the regulation of GST. In accordance with a recent
report [24], we also observed that surgical menopause and ERT
did not alter CAT expression. CAT is especially important in the
case of limited glutathione content or reduced GSH-Px activity
and plays a signiﬁcant role in the development of tolerance to
oxidative stress in the adaptive response of cells [40]. We could
hypothesize that the regulation of this enzyme was not inﬂu-
enced by E2 levels because of the variations in glutathione and
GSH-Px expression; new studies are needed to address this
speciﬁc mechanism.
In summary, the present study showed that circulating redox
status is closely correlated to estrogen levels. In addition, surgical
menopause associated with increased risk to develop oxidative
stress via downregulation of antioxidant genes expression. Estro-
gen replacement therapy is able to restore antioxidant status and
may be effective in the prevention of morbidity related to the
oxidative stress after oophorectomy, even though wider long-term
studies are required in order to better understand the inﬂuence of
the acute E2 deprivation and of the antioxidant system activity on
the pathogenesis of menopause-related morbidity. These ﬁndings
strongly suggest that sex hormones may control, almost in part,
antioxidant gene expression. Moreover, this study support that
gender differences in the pathophysiology of diseases may depend
on redox biology.References
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